PREPARATION AND COMPARATIVE EVALUATION OF FOUR DIFFERENT OIL ADJUVANTED VACCINES AGAINST AVIAN INFLUENZA DISEASE

Avian Influenza virus causes one of the most devastating viral disease in poultry industry and is distributed worldwide Bird flu vaccine with H9N2 strain of avian influenza virus was prepared using four different adjuvants i.e. Eolane-130, Eolane-150, Eolane-170 and Montanide oil ISA 70 MVG. Immune...

Full description

Saved in:
Bibliographic Details
Published in:Pakistan journal of science 2022-12, Vol.73 (4)
Main Author: S. A. Chughtai
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Avian Influenza virus causes one of the most devastating viral disease in poultry industry and is distributed worldwide Bird flu vaccine with H9N2 strain of avian influenza virus was prepared using four different adjuvants i.e. Eolane-130, Eolane-150, Eolane-170 and Montanide oil ISA 70 MVG. Immune response of all the vaccinated and control groups after single as well as booster doses was evaluated in layer birds through Haemagglutination inhibition test. Single dose showed poor immune response while booster doses gave better response with all the vaccines. In present study, results of Haemagglutination Inhibition Test conducted on serum samples of four vaccinated and one control group indicated that the group vaccinated with Eolane-130 showed highest level of antibodies titer (GMT=576.00) on 63rd day which later declined. While the highest antibodies level recorded in groups vaccinated with Eolane-150, Eolane-170, Montanide oil adjuvanted vaccines and control groups were 400 GMT, 422 GMT, 284.4 GMT and 4 GMT respectively. All the vaccinated groups showed 100% protection when challenged with live Avian Influenza (H9 strain) virus on 63rd day. Chicken immunized with all oil adjuvanted vaccines showed no clinical signs, disease and mortality. All the vaccinated groups showed GMT titer higher than the protective GMT titer i.e. 67.29 until the end of trial.
ISSN:0030-9877
2411-0930
DOI:10.57041/pjs.v73i4.380